Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

FDA Grants Priority Review to Frontline Nivolumab Plus Chemo for Unresectable or Metastatic Urothelial Carcinoma

December 5th 2023

The FDA has granted priority review to a supplemental biologics license application seeking the approval of nivolumab plus cisplatin-based chemotherapy as a frontline treatment option for adult patients with unresectable or metastatic urothelial carcinoma.

ADC Doublets Represent a Promising Novel Approach for Treatment-Resistant mUC

December 4th 2023

Bradley A. McGregor, MD, expands on the feasibility and safety considerations addressed through the design and methodology of the DAD study; highlights dose-limiting toxicities and early responses seen with sacituzumab govitecan plus enfortumab vedotin in treatment-resistant mUC; and explains how these results support further investigation of other ADC doublets.

Enfortumab Vedotin/Pembrolizumab Extends PFS and OS in Metastatic Urothelial Cancer

December 1st 2023

Thomas Powles, MD, MBBS, MRCP, discusses key background information about the EV-302 trial; the efficacy and safety findings from this trial; and the future implications of the data from several emerging trials in urothelial cancer.

Cretostimogene Grenadenorepvec Confers High CR Rate in NMIBC

December 1st 2023

Preliminary findings from the phase 3 BOND-003 trial showed that treatment with cretostimogene grenadenorepvec led to sustained and durable complete responses and a tolerable safety profile in patients with high-risk non-muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guerin.

FDA Grants Priority Review to sBLA for Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Cancer

December 1st 2023

The FDA has granted priority review to a supplemental biologics license application for enfortumab vedotin plus pembrolizumab for the frontline treatment of patients with locally advanced or metastatic urothelial cancer.

Nadofaragene Firadenovec Induces Durable Activity in High-Risk, BCG-Unresponsive NMIBC With CIS

November 29th 2023

Nadofaragene firadenovec-vncg led to encouraging rates of high-grade recurrence-free survival and overall survival in patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.

Dr Sonpavde on the Efficacy of Frontline Nivolumab Plus Chemotherapy in Metastatic Urothelial Carcinoma

November 29th 2023

Guru P. Sonpavde, MD, discusses the significance of data from the phase 3 CheckMate 901 trial of concurrent frontline nivolumab plus chemotherapy in metastatic or unresectable urothelial carcinoma.

Perioperative Enfortumab Vedotin Shows Antitumor Activity in Cisplatin-Ineligible MIBC

November 29th 2023

Perioperative enfortumab vedotin elicited responses in cisplatin-eligible patients with muscle-invasive bladder cancer.

Enfortumab Vedotin Plus Pembrolizumab Has Potential to Alter SOC in Frontline Urothelial Cancer

November 10th 2023

The combination of enfortumab vedotin-ejfv plus pembrolizumab represents a chemotherapy-free regimen that could alter the standard of care in the frontline treatment of all patients with metastatic urothelial carcinoma.

Dr Siefker-Radtke on the Efficacy of Erdafitinib vs Pembrolizumab in FGFR-Altered mUC

November 8th 2023

Arlene O. Siefker-Radtke, MD, discusses the efficacy of erdafitinib in patients with metastatic urothelial cancer with select FGFR alterations in the phase 3 THOR study.

Dr Jayram on the Role of Immunotherapy in Bladder Cancer

November 3rd 2023

Gautam Jayram, MD, discusses the current indications for immunotherapy agents in the bladder cancer treatment paradigm, as well as immune-related adverse effects to be aware of when treating patients who are receiving these therapies.

Bladder Cancer Programs Offer Patients Comprehensive and Cutting-Edge Care

November 3rd 2023

Gautam Jayram, MD, discusses current standards of care in the bladder cancer treatment arena, novel therapies under investigation in clinical trials that may expand the arsenal of available treatment strategies, and emphasizes the importance of implementing bladder cancer programs.

Successful Bladder Cancer Programs Rely on Old Pillars, New Innovations

November 2nd 2023

Building a successful bladder cancer program requires clinicians to employ a multifaceted approach that prioritizes good surgical practices, embraces immunotherapies with an understanding of the adverse effects that can accompany them, and being up to date in terms of options for patients.

Sacituzumab Govitecan Plus Enfortumab Vedotin Shows Early Promise in Metastatic Urothelial Carcinoma

October 31st 2023

Combining sacituzumab govitecan-hziy and enfortumab vedotin-ejfv was safe, feasible, and produced high and early response rates in patients with treatment-resistant metastatic urothelial cancer.

EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab vs Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

October 31st 2023

Terence Friedlander, MD, presents significant data from the EV-302/KEYNOTE-A39 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

EMA Validates Application for Frontline Nivolumab Plus Chemo in Advanced Urothelial Cancer

October 30th 2023

The European Medicines Agency has validated a type II variation application for the first-line combination of nivolumab and cisplatin-based chemotherapy for adult patients with unresectable or metastatic urothelial carcinoma.

Dr Catto on the Utility of Erdafitinib in High-Risk nMIBC With FGFR Alterations

October 27th 2023

James Catto, MB, ChB, PhD, FRCS, discusses the utility of erdafitinib in patients with high-risk non–muscle-invasive bladder cancer with select FGFR alterations who have received prior treatment with Bacillus Calmette–Guérin.

Dr Bilusic on Key Trials That Inform the Treatment of Patients With Urothelial Carcinoma

October 27th 2023

Marijo Bilusic, MD, PhD, discusses key trials in the treatment armamentarium for patients with urothelial carcinoma, as presented at the 2023 Sylvester Annual Oncology Updates Meeting.

Dr Narayan on the Evolving Treatment Paradigm in Metastatic Urothelial Carcinoma

October 26th 2023

Vivek K. Narayan, MD, MS, discusses potential avenues for treatment considerations in patients with metastatic urothelial carcinoma.

FDA Accepts BLA Resubmission for N-803 in BCG-Unresponsive, High-Risk NMIBC In Situ

October 26th 2023

The FDA has accepted the resubmission of a biologics license application seeking the approval of N-803 in combination with Bacillus Calmette-Guérin for the treatment of patients with BCG-unresponsive, non–muscle-invasive bladder cancer with carcinoma in situ with or without Ta or T1 disease.